Company news
Kiniksa Pharmaceuticals International, Plc (NASDAQ:KNSA) news
Kiniksa Pharmaceuticals International, Plc news releases on 6ix. Latest, Sep 4, 2026: Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare…
Press releases & updates
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
September 4, 2026
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
August 7, 2026
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
July 28, 2026
Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026
July 23, 2026
Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution
April 28, 2026
Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026
April 23, 2026
Kiniksa Pharmaceuticals Launches Targeted Direct-To-Consumer TV Campaign for ARCALYST® (rilonacept) in Recurrent Pericarditis
April 7, 2026
Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference
February 25, 2026
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution
February 24, 2026
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
February 19, 2026
Kiniksa Pharmaceuticals Provides Corporate Update
January 12, 2026
Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference
January 7, 2026
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
November 11, 2025
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
October 27, 2025
Kiniksa Pharmaceuticals to Report Third Quarter 2025 Financial Results on October 28, 2025
October 22, 2025
Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis
October 16, 2025
Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
August 27, 2025
Kiniksa Pharmaceuticals Reports Second Quarter 2025 Financial Results and Recent Portfolio Execution
July 28, 2025
Kiniksa Pharmaceuticals to Report Second Quarter 2025 Financial Results on July 29, 2025
July 23, 2025
Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis
June 4, 2025
Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis
April 29, 2025
Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution
April 28, 2025
Kiniksa Pharmaceuticals to Report First Quarter 2025 Financial Results on April 29, 2025
April 23, 2025
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Portfolio Execution
February 24, 2025
Kiniksa Pharmaceuticals Announces Development of KPL-387 in Recurrent Pericarditis and Updates Corporate Strategy
February 24, 2025
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
February 19, 2025
Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance
January 12, 2025
Kiniksa Pharmaceuticals to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 5, 2025
Kiniksa Pharmaceuticals to Present at 7th Annual Evercore ISI HealthCONx Conference
November 25, 2024
Kiniksa Pharmaceuticals to Present at Jefferies London Healthcare Conference
November 11, 2024
Kiniksa Pharmaceuticals Reports Third Quarter 2024 Financial Results and Recent Portfolio Execution
October 28, 2024
Kiniksa Pharmaceuticals Partners with GRAMMY® Award-Winning Singer-Songwriter, Carly Pearce, in Expansion of Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
October 27, 2024
Kiniksa Pharmaceuticals to Report Third Quarter 2024 Financial Results on October 29, 2024
October 21, 2024
NHL Hall-of-Famer, Henrik Lundqvist, Teams Up with Kiniksa Pharmaceuticals to Launch Life DisRPted™ Campaign to Drive Awareness of Recurrent Pericarditis
September 30, 2024
Kiniksa Pharmaceuticals to Present at 2024 Wells Fargo Healthcare Conference
August 27, 2024
Kiniksa Pharmaceuticals Reports Second Quarter 2024 Financial Results and Recent Portfolio Execution
July 22, 2024
Kiniksa Pharmaceuticals to Report Second Quarter 2024 Financial Results on July 23, 2024
July 15, 2024
Kiniksa Pharmaceuticals Commences Enrollment in Abiprubart Phase 2b Clinical Trial in Sjögren’s Disease
July 8, 2024
Kiniksa Pharmaceuticals Partners with NHL Hall-of-Famer Henrik Lundqvist to Raise Awareness of Recurrent Pericarditis
June 23, 2024
Kiniksa Pharmaceuticals Sponsors American Heart Association’s Addressing Recurrent Pericarditis Initiative
June 16, 2024
Kiniksa Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
June 3, 2024
Kiniksa Pharmaceuticals to Present at Bank of America Securities 2024 Health Care Conference
May 6, 2024
Kiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio Execution
April 22, 2024
Kiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024
April 15, 2024
Kiniksa Pharmaceuticals Announces Development Indication for Abiprubart
April 1, 2024
Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Portfolio Execution
February 27, 2024
Kiniksa Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024
February 20, 2024
Kiniksa Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference
January 1, 2024
Kiniksa Pharmaceuticals Reports Third Quarter 2023 Financial Results and Recent Portfolio Execution
October 30, 2023
Kiniksa Pharmaceuticals to Report Third Quarter 2023 Financial Results on October 31, 2023
October 23, 2023